Cargando…
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provide...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744553/ https://www.ncbi.nlm.nih.gov/pubmed/31534988 http://dx.doi.org/10.1016/j.dib.2019.104277 |
_version_ | 1783451394369388544 |
---|---|
author | Donohue, James Kerwin, Edward Sethi, Sanjay Haumann, Brett Pendyala, Srikanth Dean, Lorna Barnes, Chris N. Moran, Edmund J. Crater, Glenn |
author_facet | Donohue, James Kerwin, Edward Sethi, Sanjay Haumann, Brett Pendyala, Srikanth Dean, Lorna Barnes, Chris N. Moran, Edmund J. Crater, Glenn |
author_sort | Donohue, James |
collection | PubMed |
description | This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted. Further interpretation and discussion of the data are demonstrated in the article “Revefenacin, a Once-daily, Lung-selective, Long-acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” [1] |
format | Online Article Text |
id | pubmed-6744553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-67445532019-09-18 Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease Donohue, James Kerwin, Edward Sethi, Sanjay Haumann, Brett Pendyala, Srikanth Dean, Lorna Barnes, Chris N. Moran, Edmund J. Crater, Glenn Data Brief Medicine and Dentistry This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted. Further interpretation and discussion of the data are demonstrated in the article “Revefenacin, a Once-daily, Lung-selective, Long-acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” [1] Elsevier 2019-08-22 /pmc/articles/PMC6744553/ /pubmed/31534988 http://dx.doi.org/10.1016/j.dib.2019.104277 Text en © 2019 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Medicine and Dentistry Donohue, James Kerwin, Edward Sethi, Sanjay Haumann, Brett Pendyala, Srikanth Dean, Lorna Barnes, Chris N. Moran, Edmund J. Crater, Glenn Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title_full | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title_fullStr | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title_full_unstemmed | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title_short | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
title_sort | data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
topic | Medicine and Dentistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744553/ https://www.ncbi.nlm.nih.gov/pubmed/31534988 http://dx.doi.org/10.1016/j.dib.2019.104277 |
work_keys_str_mv | AT donohuejames dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT kerwinedward dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT sethisanjay dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT haumannbrett dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT pendyalasrikanth dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT deanlorna dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT barneschrisn dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT moranedmundj dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT craterglenn dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease |